Cargando…
MEDB-63. Deciphering the role of LIN28B in Group 3 medulloblastoma
BACKGROUND: Children with Group 3 medulloblastoma (MB) have a very poor long-term outcome and many do not survive beyond 5 years. Several drivers for Group 3 MB have been identified but none have resulted in targeted therapy to date. LIN28B is a stem cell factor that is upregulated in Group 3 medull...
Autores principales: | Shahab, Shubin, Sun, Jessica, Schnepp, Robert, MacDonald, Tobey, Kenney, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164639/ http://dx.doi.org/10.1093/neuonc/noac079.437 |
Ejemplares similares
-
EMBR-12. TARGETING THE RNA-BINDING PROTEIN LIN28B IN GROUP 3 MEDULLOBLASTOMA
por: Shahab, Shubin, et al.
Publicado: (2021) -
MDB-03. DFMO AS A TREATMENT STRATEGY IN GROUP 3 MEDULLOBLASTOMA
por: Shahab, Shubin, et al.
Publicado: (2023) -
MEDB-87. Transcriptome-driven drug repurposing in group 3 medulloblastoma
por: Doss, David, et al.
Publicado: (2022) -
MEDB-33. The landscape of ecDNA in medulloblastoma
por: Chapman, Owen, et al.
Publicado: (2022) -
MEDB-28. CDK9 is a druggable mediator sustaining Myc-driven circuitry in medulloblastoma
por: Madhavan, Krishna, et al.
Publicado: (2022)